Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Pfizer Inc.
EIR
•Pfizer Inc.•September 30, 2014

Pfizer Inc. – FDA EIR, Sep 30, 2014

Record Details

An FDA inspection of Pfizer Inc. Groton Laboratories in Groton, CT, occurred from September 16 to September 30, 2014. This surveillance inspection focused on Good Laboratory Practice (GLP) and Bioresearch Monitoring for Human Drugs, ensuring compliance with regulatory framework 21 CFR Part 58. The inspection was initiated at the request of the Center for Drug Evaluation and Research (CDER).

The facility's Drug Safety Research and Development (DSRD) unit, which conducts safety pharmacology and toxicology studies for human drugs and biologics, was a primary focus. Records reviewed included organizational charts, Master Schedules, Standard Operating Procedures (SOPs), study protocols, and raw data. Two studies were audited: "One Month Oral Toxicity Study of PF-06282999 In Dogs" and "46-Day Intravenous Toxicity Study of PF-06650808 in Monkeys with a 39-Day Recovery."

The main violation identified was documented on a one-item Form FDA 483 for study 13GR115. It stated that "The study director failed to assure that the protocol, including any change, was approved and was followed," indicating a procedural deviation. As a required action, Pfizer management committed to submitting a voluntary written response to the observation within 15 business days. The district office recommended a "Voluntary Action Indicated" (VAI) classification and referred the final classification to CDER, suggesting that corrective actions are necessary but do not require severe enforcement.

Company
Pfizer Inc.
Inspection date
September 30, 2014
Product type
drugs
Office
New England District Office
People
  • Angel S. Johnson (other)
  • Matthew C. Watson
  • Maura Rooney (issuing_officer)
  • Abhijit Raha (other)
View Company Profile

ID · 1b616e25-36ff-4336-a7a1-8b42381c8a52

Violation Codes1
21 CFR 58

Full citation text and observation details available on the Dashboard.

Other documents for Pfizer Inc.
  • 483 - 2024-12-13December 13, 2024
  • EIR - 2021-01-08January 8, 2021
  • EIR - 2018-11-02November 2, 2018
  • EIR - 2018-07-18July 18, 2018
  • EIR - 2018-06-21June 21, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pfizer Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.